In these male patients of myeloid malignancies, we observed three different scenarios: (i) UBA1 variants as the main clone, (ii) UBA1 variants as subclonal events in combination with known leukemic driver events, and (iii) UBA1 variants as a secondary major driver event following treatment. This evidence concerns the gene UBA1 and myeloid neoplasm.